Meag Munich Ergo’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $70.2M | Buy |
632,892
+158,552
| +33% | +$16.9M | 1.98% | 10 |
|
|
2025
Q1 | $53.1M | Sell |
474,340
-413,575
| -47% | -$42.7M | 1.56% | 25 |
|
|
2024
Q4 | $81.7M | Sell |
887,915
-45,833
| -5% | -$4.13M | 2.58% | 4 |
|
|
2024
Q3 | $78.3M | Sell |
933,748
-30,318
| -3% | -$2.31M | 2.46% | 4 |
|
|
2024
Q2 | $66.1M | Buy |
964,066
+87,167
| +10% | +$5.82M | 2.2% | 4 |
|
|
2024
Q1 | $64.2M | Sell |
876,899
-8,086
| -0.9% | -$622K | 2.32% | 5 |
|
|
2023
Q4 | $71.7M | Buy |
884,985
+264,282
| +43% | +$20.6M | 2.72% | 3 |
|
|
2023
Q3 | $46.5M | Buy |
620,703
+115,865
| +23% | +$8.91M | 2.03% | 11 |
|
|
2023
Q2 | $38.9M | Buy |
504,838
+484,502
| +2,382% | +$38.6M | 1.7% | 20 |
|
|
2023
Q1 | $1.69M | Sell |
20,336
-12,998
| -39% | -$1.08M | 0.08% | 103 |
|
|
2022
Q4 | $2.86M | Buy |
33,334
+18,554
| +126% | +$1.47M | 0.15% | 96 |
|
|
2022
Q3 | $912K | Sell |
14,780
-3,500
| -19% | -$221K | 0.06% | 143 |
|
|
2022
Q2 | $1.13M | Buy |
18,280
+10,780
| +144% | +$667K | 0.07% | 137 |
|
|
2022
Q1 | $451K | Buy |
7,500
+3,300
| +79% | +$211K | 0.03% | 171 |
|
|
2021
Q4 | $309K | Hold |
4,200
| – | – | 0.02% | 160 |
|
|
2021
Q3 | $293K | Sell |
4,200
-34,693
| -89% | -$2.44M | 0.05% | 175 |
|
|
2021
Q2 | $2.68M | Sell |
38,893
-17,547
| -31% | -$1.17M | 0.26% | 101 |
|
|
2021
Q1 | $3.65M | Buy |
56,440
+21,970
| +64% | +$1.42M | 0.37% | 74 |
|
|
2020
Q4 | $1.95M | Buy |
34,470
+6,000
| +21% | +$362K | 0.45% | 65 |
|
|
2020
Q3 | $1.8M | Buy |
28,470
+7,686
| +37% | +$533K | 0.33% | 77 |
|
|
2020
Q2 | $1.6M | Sell |
20,784
-12,070
| -37% | -$925K | 0.3% | 93 |
|
|
2020
Q1 | $2.46M | Sell |
32,854
-60,766
| -65% | -$4.2M | 0.58% | 49 |
|
|
2019
Q4 | $6.08M | Sell |
93,620
-37,214
| -28% | -$2.42M | 0.65% | 39 |
|
|
2019
Q3 | $8.2M | Buy |
130,834
+59,865
| +84% | +$3.91M | 0.42% | 58 |
|
|
2019
Q2 | $4.77M | Buy |
70,969
+21,540
| +44% | +$1.42M | 0.37% | 64 |
|
|
2019
Q1 | $3.15M | Sell |
49,429
-49,481
| -50% | -$3.29M | 0.26% | 86 |
|
|
2018
Q4 | $6.24M | Buy |
98,910
+9,056
| +10% | +$633K | 0.77% | 33 |
|
|
2018
Q3 | $6.84M | Buy |
89,854
+17,027
| +23% | +$1.29M | 0.41% | 72 |
|
|
2018
Q2 | $5.17M | Sell |
72,827
-35,751
| -33% | -$2.52M | 0.32% | 103 |
|
|
2018
Q1 | $8.09M | Buy |
108,578
+5,787
| +6% | +$460K | 0.33% | 93 |
|
|
2017
Q4 | $7.49M | Sell |
102,791
-260,952
| -72% | -$19.8M | 0.29% | 102 |
|
|
2017
Q3 | $29.5M | Buy |
363,743
+128,691
| +55% | +$9.84M | 1.21% | 13 |
|
|
2017
Q2 | $16.6M | Sell |
235,052
-95,870
| -29% | -$6.38M | 0.74% | 33 |
|
|
2017
Q1 | $22.3M | Buy |
330,922
+194,703
| +143% | +$13.7M | 0.88% | 16 |
|
|
2016
Q4 | $9.88M | Buy |
136,219
+75,585
| +125% | +$5.62M | 0.46% | 70 |
|
|
2016
Q3 | $4.72M | Sell |
60,634
-170,090
| -74% | -$13.8M | 0.23% | 123 |
|
|
2016
Q2 | $19.2M | Sell |
230,724
-83,897
| -27% | -$7.45M | 1.74% | 15 |
|
|
2016
Q1 | $29.1M | Buy |
314,621
+89,644
| +40% | +$8.08M | 1.5% | 9 |
|
|
2015
Q4 | $23M | Buy |
224,977
+93,001
| +70% | +$9.68M | 1.15% | 15 |
|
|
2015
Q3 | $13M | Sell |
131,976
-1,845
| -1% | -$205K | 0.69% | 43 |
|
|
2015
Q2 | $15.7M | Buy |
+133,821
| New | +$14.6M | 0.81% | 34 |
|
|
2013
Q4 | – | Sell |
-2,324
| Closed | -$146K | – | 258 |
|
|
2013
Q3 | $146K | Sell |
2,324
-47,364
| -95% | -$2.83M | 0.01% | 218 |
|
|
2013
Q2 | $2.55M | Buy |
+49,688
| New | +$2.59M | 0.19% | 122 |
|
Other funds holding GILD
Meag Munich Ergo's GILD Position: Q2 2025 in Review
Meag Munich Ergo increased its Gilead Sciences (GILD) stake by 33% in Q2 2025, buying an estimated $16.9M and bringing the position to 632,892 shares worth $70.2M. The position accounts for 1.98% of the portfolio, ranked #10.
Meag Munich Ergo first reported a position in GILD in Q2 2013 and has held it in 43 quarters since. The position peaked at $81.7M in Q4 2024. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.
- Meag Munich Ergo held 632,892 shares of Gilead Sciences worth $70.2M as of Q2 2025.
- Meag Munich Ergo bought 158,552 Gilead Sciences shares in Q2 2025, an estimated $16.9M.
- Gilead Sciences made up 1.98% of Meag Munich Ergo's portfolio in Q2 2025, its #10 holding.
- Meag Munich Ergo first reported a position in Gilead Sciences in Q2 2013 and has held it in 43 quarters since.
- Meag Munich Ergo's Gilead Sciences position peaked at $81.7M in Q4 2024.
- 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.
Based on Meag Munich Ergo's 13F filing for Q2 2025, filed 16 Jul 2025.